



WEDNESDAY 18th May 2016 COMMENCING 09:30 AM

AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST

LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | Enclosure |
|---|----------------------------|
| 1. Welcome and introduction | |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/0516 |
| 5. Chairman's report | |
| 6. Appraisal 1: Full Submission
Dulaglutide (Trulicity[®]) indicated in adults with type 2 diabetes mellitus to improve glycaemic control as: monotherapy when diet and exercise alone do not provide adequate glycaemic control in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications; as add on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control | 2/AWMSG/0516
Appendices |
| 7. Citizens Jury | 3/AWMSG/0516 |
| 8. Appraisal 2: Full Submission
Guanfacine (Intuniv[®]) for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures | 4/AWMSG/0516
Appendices |
| 9. Feedback from AWPAG meeting held 9th March 2016 | 5/AWMSG/0516 |
| 10. National Prescribing Indicators 2015–2016 – Analysis of Prescribing Data to December 2015 – for information | 6/AWMSG/0516 |

11. **Appraisal 3: Full Submission**
Pasireotide (Signifor[®]) for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue

7/AWMSG/0516
Appendices

Date of next meeting: 15th June 2016 in Cardiff